Financial Performance - Consolidated revenue grew by 7.8% and system-wide revenue increased by 8.2% from the year ended December 31, 2024, to the year ended December 31, 2025[27]. - For the year ended December 31, 2025, consolidated revenues reached $1.023 billion, a 7.8% increase from $948.9 million in 2024[83]. - Adjusted EBITDA for the year ended December 31, 2025, was $230.2 million, representing an Adjusted EBITDA margin of 22.5%[83]. - 58% of consolidated revenues came from commercial payors, with government payors contributing 29% and self-pay, liens, and other payors making up the remainder[69]. Market Overview - The U.S. market for diagnostic imaging services was approximately $140 billion as of December 31, 2024, with a CAGR of 4.2% from 2019 to 2024[30]. - Management estimates that the diagnostic imaging services market will continue to grow at a mid-single digit rate between 2024 and 2030, driven by increasing utilization of advanced imaging and an aging population[31]. - The outpatient diagnostic imaging services market is highly fragmented, with approximately 6,000 independent diagnostic testing facilities (IDTFs) in the U.S. as of December 31, 2025[35]. Advanced Imaging - Advanced imaging accounted for 52% of consolidated revenue and 63% of system-wide revenue for the year ended December 31, 2025[50]. - Advanced imaging payments per procedure were approximately 330% of routine imaging payments per procedure as of December 31, 2025[41]. Operational Efficiency - The company has implemented third-party AI solutions, resulting in faster scan times and improved clinical efficiency[29]. - AI implementation is expected to reduce consolidated expenses related to third-party radiologist salaries, which totaled approximately $40 million in 2025[81]. - Investments in technology and workflow design aim to enhance operational performance and reduce administrative burdens, focusing on standardized protocols and scheduling optimization[146]. Growth Strategy - The company opened 13 de novo centers since December 31, 2023, including nine in 2025, to expand its presence in underserved areas[90]. - The average initial capital investment for de novo centers is $4.0 million, targeting an annual Adjusted EBITDA contribution of $1.0 million to $3.0 million[88]. - The company has a disciplined acquisition strategy, averaging an Adjusted EBITDA multiple of eight to nine times for medium to large imaging center companies[92]. Patient Satisfaction - The company’s patient Net Promoter Score (NPS) was 91, with an overall patient satisfaction rate of 97% as of December 31, 2025[57]. - The company received referrals from over 32,000 physician practices for imaging services in 2025, indicating a broad referral base[71]. Regulatory Environment - The company must comply with stringent federal and state regulatory requirements to participate in Medicare and Medicaid programs, which may affect service costs and payment timing[100]. - The Stark Law prohibits physicians from referring Medicare patients to entities in which they have a financial interest, with penalties including exclusion from Medicare and civil monetary penalties[106]. - The Patient Protection and Affordable Care Act increased the equipment utilization factor for advanced diagnostic imaging services, leading to reduced federal reimbursement rates for medical imaging[118]. - Increased enforcement activities regarding Medicare and Medicaid fraud regulations could adversely affect the company's financial performance[113]. - Future changes in healthcare reform legislation may lead to higher uninsured populations and reduced reimbursement rates, stressing healthcare institution finances[120]. Workforce and Compliance - The company employs 4,064 full-time, 271 part-time, and 684 as-needed employees as of December 31, 2025, including 322 full-time and 10 part-time radiologists[142]. - The company focuses on building sustainable pipelines for critical clinical roles, particularly radiologists and imaging technologists, to expand access to care[143]. - The company has implemented competitive compensation and performance-aligned incentives to attract and retain skilled professionals[144]. - The company maintains a compliance program to adhere to federal and state laws applicable to healthcare entities, including a Chief Compliance Officer and audit committee[137]. Financial Risks - Negative changes in governmental capitation or fee-for-service rates could significantly adversely impact the company's revenue and financial results[102]. - The company faces potential scrutiny from government audits, which could result in significant repayment obligations and penalties[112]. - Interest expense is affected by changes in short-term interest rates due to fixed and variable interest rate debt instruments[414]. - A hypothetical 1% increase in adjusted SOFR rates would result in an increase of approximately $8.3 million in annual interest expense[416].
Lumexa Imaging Holdings(LMRI) - 2025 Q4 - Annual Report